Publication | Closed Access

Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder

PsychopathologyPsychiatryAddictionMedicinePsychotropic MedicationAtomoxetine TreatmentDepressionPsychopharmacologyNeuropharmacologySocial SciencesPsychiatric DisorderAttention-deficit/hyperactivity DisorderPsychology